Case Report Open Access
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. May 15, 2024; 16(5): 2219-2224
Published online May 15, 2024. doi: 10.4251/wjgo.v16.i5.2219
Chemoradiotherapy plus tislelizumab for mismatch repair proficient rectal cancer with supraclavicular lymph node metastasis: A case report
Wen-Tao Zhong, The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, Guangdong Province, China
Yuan Lv, Qian-Yu Wang, Gang Chen, Jun-Feng Du, Department of General Surgery, The 7th Medical Center of PLA General Hospital, Beijing 100700, China
Ran An, Department of Pathology, The 7th Medical Center of PLA General Hospital, Beijing 100700, China
ORCID number: Wen-Tao Zhong (0000-0002-6268-1898); Gang Chen (0009-0000-1264-1073); Jun-Feng Du (0000-0002-8482-4271).
Co-first authors: Wen-Tao Zhong and Yuan Lv.
Co-corresponding authors: Gang Chen and Jun-Feng Du.
Author contributions: Zhong WT and Lv Y contributed to data collection, the conceptualization and drafted the manuscript; An R and Wang QY analyzed the data; Chen G and Du JF were involved in the writing, review and editing of the manuscript; all authors were involved in the critical review of the results and have contributed to, read, and approved the final manuscript. Zhong WT and Lv Y contributed equally to this work as co-first authors. The reasons are as following. This research was conducted as a collaborative effort. Zhong WT and Lv Y collaborated on the writing and data analysis of the article, they made equal and substantial efforts throughout the entire research process. The designation of their co-first authors accurately reflect the distribution of relevant responsibilities and burdens and ultimately improves the quality of the paper. Chen G and Du JF were designated as co-corresponding authors, because the entire research team is composed of researchers with different professional backgrounds, and the designation of co-corresponding authors best reflects this diversity. Chen G and Du JF participated in the writing, review and editing of the manuscript, through professional analysis and editing, the quality of the article has been significantly improved. In conclusion, our co-authors and co-corresponding authors designations are completely correct and confirmed by all authors.
Supported by National Natural Science Foundation of China, No. 81870393.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jun-Feng Du, MD, Adjunct Professor, Department of General Surgery, The 7th Medical Center of PLA General Hospital, No. 5 NanmenCang, Beijing 100700, China. dujunfeng@301hospital.com.cn
Received: November 14, 2023
Peer-review started: November 14, 2023
First decision: January 31, 2024
Revised: February 8, 2024
Accepted: March 14, 2024
Article in press: March 14, 2024
Published online: May 15, 2024
Processing time: 177 Days and 8.4 Hours

Abstract
BACKGROUND

According to the latest report, colorectal cancer is still one of the most prevalent cancers, with the third highest incidence and mortality worldwide. Treatment of advanced rectal cancer with distant metastases is usually unsatisfactory, especially for mismatch repair proficient (pMMR) rectal cancer, which leads to poor prognosis and recurrence.

CASE SUMMARY

We report a case of a pMMR rectal adenocarcinoma with metastases of multiple lymph nodes, including the left supraclavicular lymph node, before treatment in a 70-year-old man. He received full courses of chemoradiotherapy (CRT) followed by 4 cycles of programmed death 1 inhibitor Tislelizumab, and a pathologic complete response (pCR) was achieved, and the lesion of the left supraclavicular lymph node also disappeared.

CONCLUSION

pMMR advanced rectal cancer with preserved intact distant metastatic lymph nodes may benefit from full-course CRT combined with immunotherapy.

Key Words: Rectal cancer, Metastasis, Chemoradiotherapy, Immunotherapy, Prognosis, Case report

Core Tip: Rectal cancer is a clinically common malignancy and the mainstream treatment methods are chemoradiotherapy (CRT) and surgery. Advanced rectal cancer is often associated with distant organs and lymph node metastasis. We report a case of mismatch repair proficient rectal cancer with left supraclavicular lymph node metastasis. The patient received 4 cycles of CRT combined with immunotherapy and achieved pCR. This case provides a rare clinical experience for such patients.



INTRODUCTION

Clinical trials in the treatment of advanced solid tumors using programmed death 1 (PD-1) inhibitors are being conducted extensively. Recent results have shown that PD-1 blockade antibody has significant therapeutic efficacy in patients with mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H) colorectal cancer (CRC)[1,2], but these patients account for only 15% of all CRC patients[3]. In addition, clinical trials of immunotherapy for patients with mismatch repair proficient (pMMR) CRC are deficient. Here, we report a case of a pMMR rectal adenocarcinoma with metastases of multiple lymph nodes before treatment, including the left supraclavicular lymph node, in a 70-year-old man. He received full courses of chemoradiotherapy (CRT) followed by 4 cycles of PD-1 inhibitor Tislelizumab, a complete pathological response was achieved, and the lesion of the left supraclavicular lymph node also disappeared.

CASE PRESENTATION
Chief complaints

A 70-year-old Chinese man was admitted to our hospital complaining of difficulty in defecation for 1 month.

History of present illness

Upon admission, the patient underwent endoscopy, which detected a cyclo-intestinal luminal growth mass, which was diagnosed as a poorly differentiated adenocarcinoma by pathologic examination. 18F-FDG PET/CT was performed and metastasis to the left supraclavicular lymph node was found. The patient underwent enterostomy due to difficulty in defecation.

History of past illness

The patient had hypertension for more than 10 years, and kept taking medicine to control his blood pressure.

Personal and family history

The patient denied any family history of rectal cancer or psychological or genetic disorders.

Physical examination

All relevant physical examinations showed no significant abnormality and vital signs were stable.

Laboratory examinations

Tumor markers in serum including carcinoembryonic antigen, cancer antigen 199, CA125 and CA153 were all within the normal ranges, whereas the level of CA724 increased to 8.9 ng/mL (reference range 0-5.3 ng/mL).

Imaging examinations

18F-FDG PET/CT was performed to detect metastases (Figure 1A). It revealed metastases of multiple lymph nodes, including the left supraclavicular lymph node (Figure 1B) and a high uptake in the rectum (Figure 1C).

Figure 1
Figure 1 18F-FDG PET/CT image before and after treatment. A: 18F-FDG PET/CT image before treatment. The number is time of examination; B: Metastatic lymph node in the clavicle before treatment. The orange arrow indicates the lymph node; C: The rectal lesion before treatment. The lesion is indicated by the blue arrows; D: 18F-FDG PET/CT image after treatment. The number is time of examination; E: Disappearance of the metastatic lymph node after treatment; F: The rectal lesion with reduced uptake after treatment.
Further diagnostic work-up

The immunohistochemistry demonstrated that the patient was positive for all four proteins associated with mismatch repair (MMR) status (Figure 2A-D), suggesting a pMMR rectal cancer, and the tumor proportion score of programmed cell death-ligand 1 was 8% (Figure 2E). We then compared the changes in CD8+ T cell/effector regulatory T cell (CD8/eTreg) ratio before and after treatment, and found that the ratio increased from 2.79 to 3.26 (Figure 3).

Figure 2
Figure 2 Histopathological analysis and immunohistochemical staining of the biopsy specimen. A: MLH1 is positive in tumor cells; B: MSH2 is positive in tumor cells; C: MSH6 is positive in tumor cells; D: PMS2 is positive in tumor cells; E: High expression of programmed cell death-ligand 1 in the specimen.
Figure 3
Figure 3 Immunohistochemical staining of CD8+ T cell and effector regulatory T cell before and after treatment. A: CD8+ T cell in tumor cells before treatment; B: effector regulatory T cell (eTreg) in tumor cells before treatment; C: CD8+ T cell in tumor cells after treatment; D: eTreg in tumor cells after treatment.
FINAL DIAGNOSIS

Combined with the medical history, the patient was diagnosed with rectal cancer with the left supraclavicular lymph node metastasis, which was staged as cT3N2bM1a (c-stage IVA), according to the AJCC 8th TNM staging system.

TREATMENT

The patient received 4 cycles of CRT with capecitabine and radiotherapy at a dose of 50.4 Gy, followed by PD-1 inhibitor Tislelizumab 200 mg once every three weeks.

OUTCOME AND FOLLOW-UP

The patient did not have any adverse effects related to the PD-1 inhibitor during the follow-up. After finishing the last treatment, the patient was admitted to the hospital for re-examination, unexpectedly, there was no significant uptake of the previous metastases of the multiple lymph nodes, including the left supraclavicular lymph node (Figure 1D and E) and no uptake of the rectal lesion could be seen on the 18F-FDG PET/CT (Figure 1F). He then underwent radical resection of the rectal lesion, and no tumor cell was found under microscope, which suggested that the patient achieved a pCR.

DISCUSSION

The 5-year survival rate of CRC patients is still low in spite of various treatments used[4,5]. Based on the mutation patterns, CRC can be categorized into two distinct groups: the patients with dMMR, which tends to have high overall tumor mutation burden, and the patients with pMMR, with much lower tumor mutation burden[6]. dMMR tumors can be certified by the lack of immunohistochemical staining of the MMR proteins MLH1, MSH2, MSH6, or PMS2, which tend to have a high density of immune cell infiltration, known as "hot tumor", thus these patients have a better prognosis generally, but the number of the patients was low[7].

Currently, many phase 2 and 3 clinical trials have been carried out in the treatment of various solid tumors, including CRC, using PD-1 inhibitors. In a phase 2 clinical trial by Cercek, 100% dMMR/MSI-H rectal cancer patients, who received PD-1 inhibitor treatment and standard CRT followed by surgery, achieved clinical complete response, and no patient had disease progression or recurrence[8]. The KEYNOTE 016 study[9] evaluated the efficacy of pembrolizumab in metastatic CRC patients. All patients with dMMR/MSI-H metastatic CRC displayed favorable antitumor activity with an objective remission rate (ORR) of 40% (4/10), while none of the patients with pMMR or microsatellite stable tumor achieved ORR. The latest PANDORA trial[10] also indicated the efficacy of a neoadjuvant therapy with PD-1 inhibitor following CRT in patients with locally advanced rectal cancer (LARC), and 34.5% (19/55) of the patients achieved pCR. The above trials have shown positive therapeutic effects in dMMR/MSI-H CRC patients treated with PD-1 inhibitor alone or combined with other treatments, but pMMR CRC patients showed little benefit from immunotherapy. The main reason for this phenomenon is the “cold” characteristic of pMMR tumor. Therefore, how to induce pMMR tumor to be “hot” has been a major concern.

As observed in the VOLTAGE-A study[11], 37 patients received 5 cycles of CRT and Nivolumab and about 30% of the patients achieved pCR. Similarly, the study by Gao et al[12] confirmed the effectiveness of immunotherapy for pMMR LARC. One possible explanation is that the induction of tumor cell death after radiotherapy increases the release of tumor antigens and pro-inflammatory mediators which promote infiltration of tumor-infiltrating lymphocytes at the primary site and triggers anti-tumor responses[13,14]. Simultaneously, according to recent studies, maintaining the integrity of the lymph nodes is significant to immunotherapy efficiency[15,16], which suggested that immunotherapy induces activation of migratory dendritic cell in tumor-draining lymph node and increases anti-tumor capacity by decreasing Treg and activating effector T cells in the sentinel lymph node and peripheral blood, increasing anti-tumor capacity.

CONCLUSION

We presented a rare case of pMMR advanced rectal cancer with distant lymph node metastasis treated with CRT and Tislelizumab with good efficacy. Immunotherapy combined with standard CRT as a conversion therapy might be a promising treatment in the advanced rectal cancer.

ACKNOWLEDGEMENTS

We appreciate the cooperation of patient and his family during the treatment.

Footnotes

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Oncology

Country/Territory of origin: China

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Hidaka E, Japan S-Editor: Qu XL L-Editor: A P-Editor: Zhang XD

References
1.  André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Van Cutsem E, Yang P, Farooqui MZH, Marinello P, Diaz LA Jr; KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383:2207-2218.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 962]  [Cited by in F6Publishing: 1371]  [Article Influence: 342.8]  [Reference Citation Analysis (0)]
2.  Chen G, Jin Y, Guan WL, Zhang RX, Xiao WW, Cai PQ, Liu M, Lin JZ, Wang FL, Li C, Quan TT, Xi SY, Zhang HZ, Pan ZZ, Wang F, Xu RH. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol. 2023;8:422-431.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 19]  [Reference Citation Analysis (0)]
3.  Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 2010;7:153-162.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 660]  [Cited by in F6Publishing: 632]  [Article Influence: 45.1]  [Reference Citation Analysis (0)]
4.  Leowattana W, Leowattana P, Leowattana T. Systemic treatment for metastatic colorectal cancer. World J Gastroenterol. 2023;29:1569-1588.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 2]  [Cited by in F6Publishing: 2]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
5.  Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17-48.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 116]  [Cited by in F6Publishing: 4919]  [Article Influence: 4919.0]  [Reference Citation Analysis (0)]
6.  Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-337.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5743]  [Cited by in F6Publishing: 6223]  [Article Influence: 518.6]  [Reference Citation Analysis (0)]
7.  Lin A, Zhang J, Luo P. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Front Immunol. 2020;11:2039.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 83]  [Cited by in F6Publishing: 157]  [Article Influence: 39.3]  [Reference Citation Analysis (0)]
8.  Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA Jr. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386:2363-2376.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 595]  [Cited by in F6Publishing: 554]  [Article Influence: 277.0]  [Reference Citation Analysis (0)]
9.  Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509-2520.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6096]  [Cited by in F6Publishing: 6657]  [Article Influence: 739.7]  [Reference Citation Analysis (0)]
10.  Grassi E, Zingaretti C, Petracci E, Corbelli J, Papiani G, Banchelli I, Valli I, Frassineti GL, Passardi A, Di Bartolomeo M, Pietrantonio F, Gelsomino F, Carandina I, Banzi M, Martella L, Bonetti AV, Boccaccino A, Molinari C, Marisi G, Ugolini G, Nanni O, Tamberi S. Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial. ESMO Open. 2023;8:101824.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
11.  Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, Fukuoka S, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Wakabayashi M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Suzuki Y, Sato A, Nishikawa H, Ito M, Yoshino T. Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer. Clin Cancer Res. 2022;28:1136-1146.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 9]  [Cited by in F6Publishing: 59]  [Article Influence: 29.5]  [Reference Citation Analysis (0)]
12.  Gao J, Zhang X, Yang Z, Zhang J, Bai Z, Deng W, Chen G, Xu R, Wei Q, Liu Y, Han J, Li A, Liu G, Sun Y, Kong D, Yao H, Zhang Z. Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer. Front Oncol. 2023;13:1057947.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 4]  [Reference Citation Analysis (0)]
13.  MOLE RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26:234-241.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 677]  [Cited by in F6Publishing: 740]  [Article Influence: 10.4]  [Reference Citation Analysis (0)]
14.  McLaughlin M, Patin EC, Pedersen M, Wilkins A, Dillon MT, Melcher AA, Harrington KJ. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020;20:203-217.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 388]  [Cited by in F6Publishing: 406]  [Article Influence: 101.5]  [Reference Citation Analysis (0)]
15.  Rahim MK, Okholm TLH, Jones KB, McCarthy EE, Liu CC, Yee JL, Tamaki SJ, Marquez DM, Tenvooren I, Wai K, Cheung A, Davidson BR, Johri V, Samad B, O'Gorman WE, Krummel MF, van Zante A, Combes AJ, Angelo M, Fong L, Algazi AP, Ha P, Spitzer MH. Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell. 2023;186:1127-1143.e18.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 70]  [Cited by in F6Publishing: 83]  [Article Influence: 83.0]  [Reference Citation Analysis (0)]
16.  Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC, Fong L, Nolan GP, Engleman EG. Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell. 2017;168:487-502.e15.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 633]  [Cited by in F6Publishing: 627]  [Article Influence: 89.6]  [Reference Citation Analysis (0)]